Drug Information

Product NDC: 0078-0972

Proprietary Name: PROMACTA

Non Proprietary Name: eltrombopag olamine

Active Ingredient(s):

Administration Route(s): ORAL


Pharmacy Class(es):
  • Increased Megakaryocyte Maturation [PE];
  • Increased Platelet Production [PE];
  • Thrombopoietin Receptor Agonist [EPC];
  • Thrombopoietin Receptor Agonists [MoA];
  • Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA];
  • Breast Cancer Resistance Protein Inhibitors [MoA];
  • UGT1A1 Inhibitors [MoA];
  • UGT1A3 Inhibitors [MoA];
  • UGT1A4 Inhibitors [MoA];
  • UGT1A6 Inhibitors [MoA];
  • UGT1A9 Inhibitors [MoA];
  • UGT2B7 Inhibitors [MoA];
  • UGT2B15 Inhibitors [MoA]

Labeler Information

Labeler Name: Novartis Pharmaceuticals Corporation
FDA Application Number: NDA207027
Marketing Category: NDA
Start Marketing Date:9/27/2018

Package Information

No. Package Code Package Description Billing Unit
10078-0972-611 CARTON in 1 KIT (0078-0972-61) > 30 PACKET in 1 CARTON (0078-0972-23) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0078-0972-19)EA

NDC Record

Field Name Field Value Definition
PRODUCT NDC0078-0972The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEPROMACTAThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEeltrombopag olamineThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEPOWDER, FOR SUSPENSIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE9/27/2018This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA207027This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMENovartis Pharmaceuticals CorporationName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEELTROMBOPAG OLAMINEThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
PHARM CLASSESIncreased Megakaryocyte Maturation [PE],Increased Platelet Production [PE],Thrombopoietin Receptor Agonist [EPC],Thrombopoietin Receptor Agonists [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],UGT1A1 Inhibitors [MoA],UGT1A3 Inhibitors [MoA],UGT1A4 Inhibitors [MoA],UGT1A6 Inhibitors [MoA],UGT1A9 Inhibitors [MoA],UGT2B7 Inhibitors [MoA],UGT2B15 Inhibitors [MoA] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 9/13/2019